{"id":568854,"date":"2025-11-14T01:57:15","date_gmt":"2025-11-14T01:57:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/568854\/"},"modified":"2025-11-14T01:57:15","modified_gmt":"2025-11-14T01:57:15","slug":"weightwatchers-to-offer-novo-nordisks-wegovy-pill-after-2026-launch","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/568854\/","title":{"rendered":"WeightWatchers to offer Novo Nordisk’s Wegovy pill after 2026 launch"},"content":{"rendered":"

Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.<\/p>\n

Shelby Knowles | Bloomberg | Getty Images<\/p>\n

WeightWatchers’<\/a> CEO said on Wednesday it plans to offer Novo Nordisk’s<\/a> much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.<\/p>\n

The collaboration is a potential boost for WeightWatchers as it emerges from bankruptcy and highlights its commitment to offer branded obesity drugs, unlike rivals that push cheaper copies in a highly competitive market.<\/p>\n

“We have been working with Novo Nordisk ahead of time to support the launch of oral weight-loss medication,” WeightWatchers CEO Tara Comonte said in an interview.<\/p>\n

“A lot of people don’t want an injection. And the convenience of a pill is going to be huge,” she said.<\/p>\n

Weight loss pills from Novo and rival Eli Lilly<\/a> are under consideration for a new, speedy U.S. review pathway that can shave months from the normal approval process.<\/p>\n

WeightWatchers could keep more customers on its platform than telehealth rivals, as doctors expect U.S. patients to switch to the branded medicines once prices come down under a deal announced last week by the White House.<\/p>\n

Lilly and Novo agreed to slash prices of their popular GLP-1 injectable drugs for U.S. government health programs and cash-paying customers.<\/p>\n

Starter doses of the weight-loss pills, if approved, will cost $149 a month for Medicare and Medicaid enrollees and for cash payers through the U.S. administration’s new TrumpRx site.<\/p>\n

“Anything that brings pricing down for these medications is good for WeightWatchers,” Comonte said.<\/p>\n

WeightWatchers is also trying to gain a stronger foothold in women’s health, including through tailored programs that offer GLP-1 medicines and hormone replacement therapy.<\/p>\n

Outside of the U.S., Germany and the UK are major markets for WeightWatchers, which had 4 million subscribers worldwide at the end of 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…\n","protected":false},"author":2,"featured_media":568855,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[24576,51,3085,102752,105,20944,4348,13731,5489,16,15,180571],"class_list":{"0":"post-568854","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-biotech-and-pharmaceuticals","9":"tag-business","10":"tag-business-news","11":"tag-eli-lilly-and-co","12":"tag-health","13":"tag-health-care-industry","14":"tag-healthcare","15":"tag-novo-nordisk-a-s","16":"tag-pharmaceuticals","17":"tag-uk","18":"tag-united-kingdom","19":"tag-ww-international-inc"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115545574424179141","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/568854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=568854"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/568854\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/568855"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=568854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=568854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=568854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}